Illumina, Inc. — Fiscal 2013 Form 10-K Summary
Business context and reporting period
Illumina develops, manufactures, and sells sequencing- and array-based systems, consumables, software, and genomic analysis services. Its customers include research institutions, government laboratories, hospitals, pharmaceutical and biotechnology companies, agricultural genomics customers, and molecular diagnostic providers.
The filing covers the 52-week fiscal year ended December 29, 2013. The fourth quarter also comprised 13 weeks. Illumina reported one reportable segment. Effective December 30, 2013, the company realigned operations around strategic markets, including life sciences, reproductive and genetic health, oncology, enterprise informatics, and emerging markets.
Financial performance and position
| Metric | Fiscal 2013 | Fiscal 2012 | Change |
|---|---|---|---|
| Revenue | $1.421 billion | $1.149 billion | +24% |
| Product revenue | $1.265 billion | $1.056 billion | +20% |
| Service and other revenue | $156.5 million | $92.7 million | +69% |
| Gross profit | $911.9 million | $773.5 million | +18% |
| Gross margin | 64.2% | 67.4% | Down 3.2 points |
| Operating income | $134.1 million | $200.8 million | Down $66.6 million |
| Net income | $125.3 million | $151.3 million | Down 17% |
| Diluted EPS | $0.90 | $1.13 | Down 20% |
| Cash flow from operations | $386.4 million | $291.9 million | +32% |
Consumables revenue increased 21% to $880.3 million, supported by growth in the HiSeq and MiSeq installed base and higher consumable usage per HiSeq instrument. Instrument revenue increased 18% to $371.5 million, primarily due to higher HiSeq shipments. Consumables represented 62% of total revenue and instruments represented 26%; service and other revenue represented the remaining 11%.
Fiscal fourth-quarter revenue was $387.3 million, compared with $309.3 million in the fourth quarter of 2012. Fourth-quarter gross profit was $259.2 million and net income was $80.7 million, compared with $203.6 million and $71.9 million, respectively, in the comparable 2012 quarter.
At year-end, cash and cash equivalents were $711.6 million and short-term investments were $454.0 million, for total cash, cash equivalents, and short-term investments of approximately $1.17 billion. Working capital was $1.295 billion, total assets were $3.019 billion, and stockholders’ equity was $1.533 billion.
Cash provided by operating activities was $386.4 million. Investing cash outflows included $523.5 million for acquisitions and $79.2 million for capital expenditures. Financing cash outflows included $50.0 million of share repurchases and $125.0 million used to retire warrants. Management stated that available liquidity and expected operating cash flow should fund near-term operating and capital needs for at least the next 12 months.
Debt consisted primarily of $920.0 million principal amount of 0.25% convertible senior notes due 2016 and $29.6 million principal amount of 0.625% convertible senior notes due February 15, 2014. Reported long-term debt, including the current portion, was $868.6 million net of unamortized discount.
Material changes versus the prior comparable period
- Revenue growth accelerated, particularly in sequencing consumables, instruments, and services.
- Gross margin declined from 67.4% to 64.2%, primarily due to product-line impairment charges, higher amortization of acquired intangible assets, and Syntrix-related legal contingencies. These items had an aggregate reported impact of approximately 3.9 percentage points.
- Operating expenses increased 36% to $777.8 million. Research and development rose 20% to $276.7 million, and selling, general, and administrative expense rose 33% to $381.0 million.
- The company recorded $115.4 million of legal contingency expense in operating expenses related primarily to Syntrix litigation and recorded a total Syntrix legal contingency accrual of $132.9 million.
- Net income declined despite higher revenue because of increased operating expenses, legal charges, amortization, impairments, and acquisition-related costs.
- The effective tax rate decreased to 21.3% from 32.1%, primarily due to a greater mix of foreign earnings taxed at lower rates and the retroactive reinstatement of the federal research and development credit.
- Acquisition activity materially increased: Illumina acquired Verinata Health, Advanced Liquid Logic, NextBio, and another development-stage company, paying net cash of $523.5 million for acquisitions during the year.
- Goodwill increased to $723.1 million from $369.3 million, and net intangible assets increased to $331.2 million from $130.2 million, principally due to acquisitions.
Guidance, outlook, commentary, and risks
Management expected continued growth in sequencing demand, the installed instrument base, sequencing consumable revenue, international sales, and applications in reproductive health, oncology, diagnostics, informatics, and other emerging markets. The company expected research and development expense and sales and distribution resources to increase during 2014.
In January 2014, Illumina announced the HiSeq X Ten and NextSeq 500 platforms. Management viewed next-generation sequencing, expanded applications, and new products as important drivers of future growth, but cautioned that product launches involve execution, customer adoption, manufacturing, quality, pricing, and product-transition risks.
- Competition is intense and includes companies with greater financial, technical, marketing, and regulatory resources.
- Demand is sensitive to government, academic, pharmaceutical, and biotechnology research funding, including NIH funding and international budget conditions.
- The company relies on rapid innovation and may face obsolescence, pricing pressure, unsuccessful launches, excess inventory, or delayed commercialization.
- Manufacturing depends on complex processes and some single-source suppliers; capacity, quality, component availability, facility disruptions, and information-system failures could impair shipments.
- Expansion into molecular diagnostics and reproductive health is subject to FDA and international regulatory approval, clinical adoption, reimbursement, and billing and collection uncertainty.
- International operations expose the company to foreign exchange, tax, geopolitical, trade, collection, and regulatory risks. International customers represented 50% of fiscal 2013 revenue.
- Intellectual-property litigation remains material. The Syntrix judgment included $115.1 million of damages and an ongoing 8% royalty on accused sales through patent expiration in 2019; Illumina appealed.
- The company had $49.0 million of uncertain tax positions, a $19.1 million valuation allowance against certain U.S. deferred tax assets, and an ongoing IRS examination for tax year 2011.
- Convertible debt may create cash requirements, dilution, or accounting gains and losses if conversion conditions are met. The 2016 notes had a $83.55 conversion price and were potentially dilutive in 2013.
Most important facts for an investor to verify
- Whether revenue and sequencing-consumable growth continued after the 2013 product launches and organizational realignment.
- The ultimate resolution, cash cost, ongoing royalty exposure, and appeal status of the Syntrix patent litigation.
- The integration, regulatory progress, reimbursement environment, and commercial contribution of Verinata, NextBio, Advanced Liquid Logic, and other acquisitions.
- The effect of acquisitions on recurring amortization, goodwill, intangible-asset impairment risk, and operating margins.
- The repayment, conversion, dilution, and cash-settlement implications of the 2014 and 2016 convertible notes and outstanding warrants.
- Whether cash generation remains sufficient to fund acquisitions, capital expenditures, debt obligations, and authorized share repurchases.
- Changes in research funding, international demand, foreign exchange exposure, regulatory approvals, reimbursement, competition, and supplier capacity.